Protective effects of aliskiren and valsartan in mice with diabetic nephropathy

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 15, Issue 4, 2014, Pages 384-395

  Wang, Weidong ^a,b   Qiu, Liru ^a   Howard, Allison ^a   Solis, Nathaniel ^a   Li, Chunling ^b   Wang, Xiaoxin ^a   Kopp, Jeffrey B ^c   Levi, Moshe ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Albuminuria; diabetic nephropathy; ER stress; lipid metabolism; renin inhibition

Indexed keywords

ALISKIREN; CONNECTIVE TISSUE GROWTH FACTOR; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHRIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PODOCIN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN; WT1 PROTEIN; X BOX BINDING PROTEIN 1; ALBUMINOID; AMIDE; CREATININE; FUMARIC ACID DERIVATIVE; G PROTEIN COUPLED RECEPTOR; MEMBRANE PROTEIN; ONCOPROTEIN; PROTECTIVE AGENT; PROTO-ONCOGENE PROTEINS C-MAS-1; TETRAZOLE DERIVATIVE; VALINE;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL DAMAGE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFICACY; ENDOPLASMIC RETICULUM STRESS; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS; HYPERGLYCEMIA; INFLAMMATION; KIDNEY; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY MASS; LIPID DIET; LIPID STORAGE; MALE; MESANGIUM; MESANGIUM CELL; METABOLIC PARAMETERS; MOUSE; NONHUMAN; PODOCYTE; PROTEIN EXPRESSION; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT DURATION; URINARY EXCRETION; ANALOGS AND DERIVATIVES; ANIMAL; COMPLICATION; DBA MOUSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GENETICS; LIPID METABOLISM; METABOLISM; PATHOLOGY;

ALBUMINS; AMIDES; ANIMALS; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; ENDOPLASMIC RETICULUM STRESS; FUMARATES; INFLAMMATION; LIPID METABOLISM; MALE; MEMBRANE PROTEINS; MESANGIAL CELLS; MICE, INBRED DBA; PODOCYTES; PROTECTIVE AGENTS; PROTEINURIA; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; VALINE;

EID: 84918570772     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320313507123     Document Type: Article

References (54)

1. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention ; 2011 :
2. Ribeiro-Oliveira A, Nogueira AI, Pereira RM, et al. The renin-angiotensin system and diabetes: An update. Vasc Health Risk Manag. 2008 ; 4: 787-803
3. Van den Meiracker AH, Man in 't Veld AJ, Admiraal PJ, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and does it affect the antihypertensive response?. J Hypertens. 1992 ; 10: 803-812
4. Wiggins KJ, Kelly DJ. Aliskiren: A novel renoprotective agent or simply an alternative to ACE inhibitors?. Kidney Int. 2009 ; 76: 23-31
5. Kelly DJ, Zhang Y, Moe G, et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia. 2007 ; 50: 2398-2404
6. Kang YS, Lee MH, Song HK, et al. Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Nephrol Dial Transplant. 2011 ; 26: 1194-1204
7. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008 ; 358: 2433-2446
8. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): Rationale and study design. Nephrol Dial Transplant. 2009 ; 24: 1663-1671
9. Dong YF, Liu L, Lai ZF, et al. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. J Hypertens. 2010 ; 28: 1554-1565
10. Zhang J, Gu C, Noble NA, et al. Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis. Am J Physiol Renal Physiol. 2011 ; 301: F723 - F732
11. Whaley-Connell A, Habibi J, Nistala R, et al. Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat. Regul Pept. 2012 ; 176: 36-44
12. Fraune C, Lange S, Krebs C, et al. AT1 antagonism and renin inhibition in mice: Pivotal role of targeting angiotensin II in chronic kidney disease. Am J Physiol Renal Physiol. 2012 ; 303: F1037 - F1048
13. Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol. 2009 ; 5: 713-721
14. Weinberg JM. Lipotoxicity. Kidney Int. 2006 ; 70: 1560-1566
15. Jiang T, Wang Z, Proctor G, et al. Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem. 2005 ; 280: 32317-32325
16. Proctor G, Jiang T, Iwahashi M, et al. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes. 2006 ; 55: 2502-2509
17. Sun L, Halaihel N, Zhang W, et al. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem. 2002 ; 277: 18919-18927
18. Wang XX, Jiang T, Shen Y, et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol. 2009 ; 297: F1587 - F1596
19. Wang XX, Jiang T, Shen Y, et al. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes. 2010 ; 59: 2916-2927
20. Wang XX, Jiang T, Shen Y, et al. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. Am J Physiol Renal Physiol. 2011 ; 300: F801 - F810
21. Wang Z, Jiang T, Li J, et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes. 2005 ; 54: 2328-2335
22. Iwai M, Kanno H, Tomono Y, et al. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. J Hypertens. 2010 ; 28: 1471-1481
23. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: A mechanistic viewpoint. Kidney Int. 2008 ; 74: 22-36
24. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. J Renin Angiotensin Aldosterone Syst. 2012 ; 13 (1). 118-21
25. Persson F, Lewis JB, Lewis EJ, et al. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol. 2011 ; 6: 1025-1031
26. Persson F, Lewis JB, Lewis EJ, et al. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care. 2010 ; 33: 2304-2309
27. Liebau MC, Lang D, Bohm J, et al. Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol. 2006 ; 290: F710 - F719
28. Wennmann DO, Hsu HH, Pavenstadt H. The renin-angiotensin-aldosterone system in podocytes. Semin Nephrol. 2012 ; 32: 377-384
29. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev. 2008 ; 4: 39-45
30. Ziyadeh FN. Mediators of diabetic renal disease: The case for tgf-Beta as the major mediator. J Am Soc Nephrol. 2004 ; 15: S55 - S57
31. Ziyadeh FN, Sharma K, Ericksen M, et al. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest. 1994 ; 93: 536-542
32. Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006 ; 69: 105-113
33. Huang Y, Noble NA, Zhang J, et al. Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int. 2007 ; 72: 45-52
34. Huang Y, Border WA, Noble NA. Functional renin receptors in renal mesangial cells. Curr Hypertens Rep. 2007 ; 9: 133-139
35. Wang XX, Jiang T, Levi M. Nuclear hormone receptors in diabetic nephropathy. Nat Rev Nephrol. 2010 ; 6: 342-351
36. Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol. 2004 ; 24: 46-53
37. Prieur X, Roszer T, Ricote M. Lipotoxicity in macrophages: Evidence from diseases associated with the metabolic syndrome. Biochim Biophys Acta. 2010 ; 1801: 327-337
38. Cases S, Smith SJ, Zheng YW, et al. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci U S A. 1998 ; 95: 13018-13023
39. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990 ; 343: 425-430
40. Strazzullo P, Galletti F. Impact of the renin-angiotensin system on lipid and carbohydrate metabolism. Curr Opin Nephrol Hypertens. 2004 ; 13: 325-332
41. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation. 2004 ; 110: 1507-1512
42. Giacchetti G, Sechi LA, Rilli S, et al. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005 ; 16: 120-126
43. Lindenmeyer MT, Rastaldi MP, Ikehata M, et al. Proteinuria and hyperglycemia induce endoplasmic reticulum stress. J Am Soc Nephrol. 2008 ; 19: 2225-2236
44. Liu G, Sun Y, Li Z, et al. Apoptosis induced by endoplasmic reticulum stress involved in diabetic kidney disease. Biochem Biophys Res Commun. 2008 ; 370: 651-656
45. Wu J, Zhang R, Torreggiani M, et al. Induction of diabetes in aged C57B6 mice results in severe nephropathy: An association with oxidative stress, endoplasmic reticulum stress, and inflammation. Am J Pathol. 2010 ; 176: 2163-2176
46. Esposito V, Grosjean F, Tan J, Huang L, Zhu L, Chen J, et al. Chop Deficiency Results in Elevated Lipopolysaccharide Induced Inflammation and Kidney Injury. Am J Physiol Renal Physiol. 2013 ; 304 (4). F440-50
47. Lhotak S, Sood S, Brimble E, et al. ER stress contributes to renal proximal tubule injury by increasing SREBP-2-mediated lipid accumulation and apoptotic cell death. Am J Physiol Renal Physiol. 2012 ; 303: F266 - F278
48. Batlle D, Soler MJ, Wysocki J. New aspects of the renin-angiotensin system: Angiotensin-converting enzyme 2 - a potential target for treatment of hypertension and diabetic nephropathy. Curr Opin Nephrol Hypertens. 2008 ; 17: 250-257
49. Tikellis C, Bernardi S, Burns WC. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens. 2011 ; 20: 62-68
50. Wong DW, Oudit GY, Reich H, et al. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol. 2007 ; 171: 438-451
51. Liu CX, Hu Q, Wang Y, et al. Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: A comparison with ACE inhibition. Mol Med. 2011 ; 17: 59-69
52. Santos SH, Braga JF, Mario EG, et al. Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). Arterioscler Thromb Vasc Biol. 2010 ; 30: 953-961
53. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 ; 367: 2204-2213
54. Rusai K, Schmaderer C, Hermans JJ, et al. Direct renin inhibition in a rat model of chronic allograft injury. Transplantation. 2011 ; 92: 999-1004